SERONO AT A GLANCE Headquarters: Geneva, Switzerland Sales: $1.3 billiona R&D expenditures: $309 million Net income: $317 million Employees: 4,600 Major products: Gonal-F (follitropin alfa) for infertility ($410 million); Rebif (interferon-beta 1a) for relapsing remitting multiple sclerosis ($380 million); Serostim and Saizen (somatropin) for treatment of HIV-associated wasting and growth retardation, respectively ($233 million total). 82% of all products are made by recombinant technology. Website: http://www.serono.com a Financial data are for 2001.

Page: 1 | 2 | 3 | Previous Page